A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

Springer Science and Business Media LLC - Tập 51 Số 3 - Trang 408-416 - 2008
Julio Rosenstock1, Melanie J. Davies2, Philip Home3, Jørgen Falck Larsen4, Christoph Koenen4, Guntram Schernthaner5
1Dallas Diabetes and Endocrine Center at Medical City, 7777 Forest Lane C-685, Dallas, TX, 75230, USA
2Cardiovascular Sciences Department, University of Leicester, Leicester, UK
3School of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
4Novo Nordisk, Bagsværd, Denmark
5Department of Medicine, Rudolfstiftung Hospital-Vienna, Vienna, Austria

Tóm tắt

Từ khóa


Tài liệu tham khảo

Riddle MC (2004) Timely initiation of basal insulin. Am J Med 116:3S–9S

Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, for the UK Prospective Diabetes Study Group (2002) Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 25:330–336

Marre M (2002) Before oral agents fail: the case for starting insulin early. Int J Obes 26(Suppl 3):S25–S30

Korytkowski M (2002) When oral agents fail: practical barriers to starting insulin. Int J Obes 26:S18–S24

Davies M (2004) The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges. Int J Obes Relat Metab Disord 28(Suppl 2):S14–S22

Koro CE, Bowlin SJ, Bourgeois N, Fedder DO (2004) Glycaemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes. Diabetes Care 27:17–20

Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group (1999) Glycaemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 281:2005–2012

Heise T, Nosek L, Ronn BB et al (2004) Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53:1614–1620

Riddle MC, Rosenstock J, Gerich J, on behalf of the Insulin Glargine 4002 Study Investigators (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080–3086

Eliaschewitz FG, Calvo C, Valbuena H et al, HOE 901/4013 LA Study Group (2006) Therapy in type 2 diabetes: insulin glargine vs NPH insulin both in combination with glimepiride. Arch Med Res 37:495–501

Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M et al (2006) Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49:442–451

Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P (2006) A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29:1269–1274

Philis-Tsimikas A, Charpentier G, Clauson P, Martinez Ravn G, Roberts VL, Thorsteinsson B (2006) Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 28:1569–1581

Home P, Kurtzhals P (2006) Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother 7:325–343

Hermansen K, Davies M (2007) Does insulin detemir have a role in reducing risk of insulin-associated weight gain. Diabetes Obes Metab 9:209–217

Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T (2007) Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time–action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 9:290–299

Porcellati F, Rossetti P, Busciantella Ricci N et al (2007) Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: A double-blind, randomized, crossover study. Diabetes Care 30:2447–2452

sanofi aventis (2005) Lantus label information, NDA 21-081/S-017. Available from http://www.fda.gov/cder/foi/label/2005/21081s017lbl.pdf, accessed 1 July 2007

Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N (2004) Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 66:193–201

Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W (2005) Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 7:56–65

Raslova K, Tamer SC, Clauson P, Karl D (2007) Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig 27:279–85

Russell-Jones D, Khan R (2007) Insulin-associated weight gain in diabetes—causes, effects and coping strategies. Diabetes Obes Metab 9:799–812